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Abstract
Background: The patients with RA benefit from early identification soon after the first clinical symptoms appear.
The 2010 ACR/EULAR classification criteria were developed to fulfill this need and their application has been
demonstrated to be effective. However, there is still room for improvement. Therefore, we aimed to evaluate the
potential of the concordant presence of RF, anti-CCP and anti-carbamylated protein antibodies to improve current
RA classification among early arthritis (EA) patients.
Methods: Data from the first visit of 1057 patients in two EA prospective cohorts were used. The serological scores
from the 2010 ACR/EULAR criteria and the concordant presence of the three RA autoantibodies were assessed
relative to a gold standard consisting of the RA classification with the 1987 ACR criteria at the 2 years of follow-up.
Results: The concordant presence of three antibodies showed predictive characteristics allowing for direct
classification as RA (positive predictive value = 96.1% and OR = 80.9). They were significantly better than the
corresponding to the high antibody titers defined as in the 2010 classification criteria (PPV = 88.8%, OR = 26.1). In
addition, the concordant presence of two antibodies was also very informative (PPV = 82.3%, OR = 15.1). These
results allowed devising a scoring system based only on antibody concordance that displayed similar overall
performance as the serological scoring system of the 2010 criteria. However, the best classification was obtained
combining the concordance and 2010 serological systems, a combination with a significant contribution from each
of the two systems.
Discussion: The concordant presence of RA autoantibodies showed an independent contribution to the
classification of EA patients that permitted increased discrimination and precision.
Keywords: Rheumatoid arthritis, Early arthritis, Disease classification, Autoantibodies, Rheumatoid factor, Anti-
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Background
Advances in the management of RA have motivated an in-
creasing interest in the early detection of the patients to
ensure they obtain all the treatment benefits [1]. Accord-
ingly, the classification criteria for RA were modified in
2010 by the ACR and the EULAR to include patients in
the early phases of the disease [2]. This objective was par-
tially attained as has been shown in multiple studies [3, 4].
Further improvements towards the early identification of
RA patients have been sought in several areas including
the presence of autoantibodies. Two of them, RF and anti-
CCP antibodies, have already an important role in the
2010 ACR/EULAR RA classification criteria. The presence
of any of these antibodies at titers over the upper limit of
normal (ULN) is scored as 2 points or as 3 points if > 3
times the ULN. These scores represent a significant frac-
tion of the 6 points required for RA classification. Other
autoantibodies, including the anti-carbamylated protein
antibodies (ACarPA), have been assessed, but none has
significantly improved the classification obtained with RF
and anti-CCP antibodies [5–7]. However, none of these
evaluations has assessed the value of the concordant pres-
ence of the RA antibodies as a classifier. It is already
known that the triple concordance is associated with ex-
tremely high specificity for RA, but analysis of its role in
RA classification among EA patients has not been per-
formed [8]. Therefore, the possibility that the concordant
presence of RA autoantibodies could improve RA classifi-
cation seemed worth to explore. Accordingly, we analyzed
the data of the 1057 patients from the two Spanish EA co-
horts included in Regueiro et al. [6] to assess the value of
new criteria considering antibody concordance.
Methods
The patient information and the antibody determinations
have already been reported [6]. Briefly, EA patients from
two prospective clinics in Madrid, PEARL [9] and IdiPAZ
[10] recruited between July 2001 and December 2014 at
PEARL and between January 1993 and December 2013 at
IdiPAZ were studied. The entry criteria for the EA clinics
were 2 or more swollen joints for less than a year and the
absence of previous treatment with Disease-Modifying
Anti-Rheumatic Drugs (DMARD). The patients were clas-
sified at the end of the 2-year follow-up according to the
1987 American College of Rheumatology (ACR) classifica-
tion criteria [11]. This classification in RA and non-RA
was used as the gold standard. The antibodies were deter-
mined in the sera from the first visit. The IgM-RF was
assessed by nephelometry, whereas anti-CCP antibodies
(ACPA) and anti-carbamylated protein antibodies
(ACarPA) were determined by ELISA. The latter was a
previously described home-made assay performed at
Santiago de Compostela using in vitro carbamylated pro-
teins from fetal calf serum as antigen [12, 13]. Briefly, we
used FCS (F-7524, Sigma-Aldrich) at 4mg/mL as a source
of proteins for in-vitro carbamylation with 1M KCNO, or
with 1M KCl as control, during 15 h at 37 °C. The effi-
ciency and percentage of carbamylation were corroborated
by HPLC in a Biochrom 30 amino-acid analyzer (Bio-
chrom, UK). The ACarPA reactivity was assessed in dupli-
cated diluted serum samples (50 μL at 1:50 dilution)
incubated in separate Nunc MaxiSorp flat-bottom 96 well
plates coated either with carbamylated or with native FCS
(0.5 μg/well). IgG antibodies were detected using ALP-
conjugated goat anti-human IgG (Jackson Immunore-
search Europe, UK). Reactivity to native FCS was
subtracted from the reactivity to carbamylated FCS. A
standard curve made with serial dilutions from a pool of
positive sera was used to measure antibody titers in arbi-
trary units. The cut-off for positivity was set as the 98%
specificity level obtained in 208 healthy controls.
The serological criteria according to the 2010 ACR/
EULAR criteria were evaluated [2]. They comprised
three levels: negative, low positive and high positive
based in RF or anti-CCP titers. Negative titers were
below the upper limit of normal (ULN), whereas low
and high positive levels were defined in relation with 3
times the ULN [2]. In addition, the new criteria based
on the concordance of the three autoantibodies were
considered. All the levels were considered as categorical
variables and only main effects were ascertained. The
OR and their 95% confidence intervals were obtained
from the logistic regression models. In addition, the
model fit was assessed with the Nagelkerke R2, and the
Akaike’s Information Criterion (AIC). The Nagelkerke
R2 estimates the predictive power of the model as a pro-
portional reduction in error variance. The AIC estimates
the relative amount of information lost by any model.
Therefore, the R2 measures increase with the predictive
power of the model, whereas the AIC reaches lower
values for the best models. Differences in AIC > 2 be-
tween two models are meaningful, whereas differences >
10 are interpreted as indicating essentially no support
for the poorer model [14]. The impact of the different
serological criteria on the overall classification (sero-
logical + non-serological criteria) was explored in the pa-
tients from PEARL, who featured all the required
information. This exploration was done in two ways.
The first consisted of changing the serological scores in
the 2010 ACR/EULAR criteria. The second classified the
patients with logistic regression that combined the non-
serological and serological criteria applying cut-offs that
were adjusted to obtain a constant sensitivity. The re-
sults of these classifications were expressed as specificity
(true nonRA/observed nonRA patients), sensitivity (true
RA/observed RA patients) and accuracy ((true nonRA +
true RA)/all patients). The statistical tests were per-
formed with R using the Jamovi application [15, 16].
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Results
The 1057 EA patients were stratified according to the
serological component of the 2010 ACR/EULAR clas-
sification [2], or according to the presence of three,
two, one, or none of the RA autoantibodies (Table 1).
Therefore, the 2010 serological criteria classified the
EA patients in three levels, whereas the concordance
criteria produced four levels. There were clear discor-
dances between the two stratifications. For example,
the 54 patients presenting only ACarPA were scored
0 in the 2010 serological criteria and 1 in the con-
cordance score, or the 46 patients at level 3 in the
2010 serological criteria that only presented 1 anti-
body (1Ab). However, the general distribution of fre-
quencies was strongly correlated between the two
systems (Gamma = 0.986, p < 10−16).
Analysis of the EA patient strata showed that the high-
est positive predictive values (PPV) were obtained with
the concordance criteria (Table 2), both in the top and
the medium levels corresponding to the concordance of
3 (3Ab) and 2 (2Ab) antibodies, respectively. The 96.1%
PPV obtained with the concordance for the 3 antibodies
would be sufficient to classify the patients as having RA.
It was also noteworthy that the PPV obtained with the
1Ab level of the concordance criteria was remarkably
similar to the PPV of the 2-points score of the 2010
serological criteria.
The OR obtained separately with the 2010 ACR/EULAR
and with the concordance criteria added a clear perspec-
tive of the high predictive power of the concordance of
the 3 antibodies (OR = 80.9) relative to the observed with
the high antibody titers in the 2010 criteria (OR = 26.1).
Furthermore, the logistic regression model incorporating
both criteria showed a significant contribution to the RA
classification of the two (Table 3). The criterion with the
largest weight was the concordance of the 3 antibodies. It
was followed in decreasing order by the 3-points score,
the concordance of 2 antibodies, the 2-points score and
the presence of only 1 antibody. The two latter classifiers
lacked a significant contribution. Therefore, we also tested
the combined criteria after deleting the stratum corre-
sponding to the presence of 1 antibody (Table 3).
Once the contribution of the two types of criteria was
demonstrated, the OR corresponding to the patients strati-
fied simultaneously with the combined criteria was deter-
mined. The results were compared with the OR
corresponding to the 2010 ACR/EULAR serological criteria
(Fig. 1). The maximum OR (OR= 94.0, 95% CI = 40.7–
217.2) was obtained with the patients that were simultan-
eously positive for the 3 antibodies and showed 3-points in
the 2010 score. The patients with 3-points and 2 concordant
antibodies followed (OR= 22.1, 95% CI = 13.5–36.0). This
latter OR was slightly smaller than the corresponding to the
3-points score of the 2010 ACR/EULAR criteria. Therefore,
only the group of patients combining the 3-points score and
the concordance for the 3 antibodies required a higher
weight than in the 2010 ACR/EULAR criteria.
It was also relevant to assess the overall performance of
the different serological criteria. This evaluation was done
determining the R2 and AIC of each model. The R2 esti-
mates the fraction of the variance that is accounted by the
criteria, whereas the AIC is proportional to the information
loss taking into consideration the complexity of the model.
The two measures were concordant in all the comparisons
(Table 4). They showed that the performances of the 2010
ACR/EULAR serological criteria and the concordance cri-
teria were almost identical (Table 4). In contrast, the com-
bination of the two types of serological criteria explained a
higher fraction of the variance and showed a lower AIC than
the separate criteria. The difference was highly favorable to
the combined models relative to the separate criteria, as the
change in AIC was > 30 and a difference of 10 is already
considered very convincing [14]. However, there were no
differences between the combined criteria including or ex-
cluding the patients that were only positive for 1 antibody.
As a final test, we also compared the classification per-
formance of criteria that included the non-serological com-
ponent together with each of the serological criteria. This
analysis was only possible with a fraction of the patients
(537 patients), but the results followed the above described:
modest improvements with the alternative models (Table 5).
The concordance criteria showed the same sensitivity than
the 2010 ACR/EULAR criteria with a 2.7% increase in spe-
cificity, and the combined criteria brought a further
Table 1 Contingency table of the EA patients according to the
2010 serological criteria and the antibody concordance criteria
Antibody concordance
Scores 0Ab 1Ab 2Ab 3Ab
2010 criteria
3 0 (0) a 46 (11.7) 170 (43.1) 178 (45.2)
2 0 (0) 75 (67.6) 33 (29.7) 3 (2.7)
0 498 (90.2) 54 (9.8) 0 (0) 0 (0)
aEach cell of the table contains the number of EA patients and, between
brackets, the percentage of the row total they represent
Table 2 Classification of the EA patients according to
serological criteria
2010 ACR/EULAR a Concordance
Score RA Non-RA PPV b Level RA Non-RA PPV
3 350 44 88.8% 3Ab 174 7 96.1%
2 47 64 42.3% 2Ab 167 36 82.3%
– – – – 1Ab 68 107 38.9%
0 129 423 23.4% 0Ab 117 381 23.5%
aThe serological criteria defined in the 2010 ACR/EULAR RA classification
criteria or by the concordance of autoantibodies
bPPV positive predictive value
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increase of 1.1% in specificity together with a 1.8% improve-
ment in sensitivity. These performance changes meant that
15 less patients were wrongly classified with the combined
criteria than with the 2010 ACR/EULAR criteria of a total
of 180 misclassified patients with the latter. As these results
depend on the scores, we attributed to each level of auto-
antibodies, we also performed a comparison of the criteria
without scores, directly from the logistic regression
(Table 5). This analysis was adjusted to obtain 80% sensitiv-
ity with all the criteria. The results were similar, showing
the same rank of specificities and accuracies. The improve-
ment in specificity with the combined criteria over the
2010 ACR/EULAR criteria was 3.1% in this comparison.
Discussion
Our results have suggested a way to improve the RA
classification of EA patients by incorporating the con-
cordant presence of 3 RA autoantibodies. This approach
is supported by various analyses. First, the higher PPV of
the concordance for 3 or 2 antibodies than of the
current serological component of the 2010 ACR/EULAR
criteria. Second, the independent contributions of the
concordance of antibodies and of the 2010 serological
criteria to prediction models that combined them. Third,
the increase in fit to the data of the combined prediction
models relative to the current serological criteria.
Fourth, the exploratory analysis showing improved per-
formance of the classification criteria that included a
combined serological component. These analyses also
lead to the realization that a sizeable set of EA patients,
in whom the three antibodies are present, deserve direct
classification as RA.
These improvements affect precision and discrimin-
ation of the classification among EA patients. They are
aspects of the classification outside the main focus of re-
cent research, which has been placed in reducing “the
Table 3 Analysis of the relative weights of the serological criteria and their combinations
2010 ACR/EULARa Concordance 2010 + Ccd. 2010 + Ccd.’
Stratum OR (95% CI) b OR (95% CI) OR (95% CI) OR (95% CI)
3 26.1 (18.0–37.8) – 7.5 (3.3–17.0) 7.0 (4.0–12.2)
2 2.4 (1.6–3.7) – 1.7 (0.8–3.7) c 1.6 (1.0–2.6) c
3Ab – 80.9 (37.0–177.1) 11.4 (3.7–35.2) 12.2 (4.9–30.2)
2Ab – 15.1 (10.0–22.9) 2.8 (1.2–6.8) 3.0 (1.7–5.3)
1Ab – 2.1 (1.4–3.0) 0.9 (0.5–1.8) c –
aThe serological criteria from the 2010 ACR/EULAR RA classification criteria, the concordance (Ccd.) of autoantibodies, and their combination without modification
(2010 + Ccd.) and after deleting the 1Ab stratum (2010 + Ccd’)
bOR and their 95% confidence intervals
cThis stratum did not contribute significantly to RA classification
Fig. 1 Odds ratio for RA classification corresponding to the EA patients stratified according to the combined 2010 ACR/EULAR and the
concordance serological criteria
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seronegative gap” [17]. That is, in identifying autoanti-
bodies that could serve as biomarkers in RA patients
lacking RF and anti-CCP. However, the new RA auto-
antibodies that are best-established cover only a fraction
of the seronegative gap [5, 13]. The gain in sensitivity
afforded has not proved sufficient to compensate for the
loss of specificity associated with increasing the number
of alternative antibodies in EA patients [5–7]. Exactly
this type of results led us and others to conclude that
ACarPA did not contribute significantly to RA classifica-
tion [6, 7]. Here, a change in perspective has shown the
possibility of turning the concordance between RA anti-
bodies into a source of useful information.
The insight leading us to consider antibody concord-
ance as a potential classifier came from the demonstra-
tion of the high specificity of this phenotype [8]. In
effect, the concordant presence of RF, anti-CCP, and
ACarPA showed specificities of 98–100% in a set of 12
case-control studies comparing: RA patients before dis-
ease development to healthy controls, and RA patients
after clinical onset to healthy controls, or healthy first-
degree relatives, or diseased controls [8]. This high spe-
cificity, which was also observed in our EA patients
(98.7%), led the authors to propose that triple antibody
positivity could be used to identify individuals at risk of
developing RA.
The most evident improvement that concordance of
antibodies could provide is the direct classification of EA
patients with 3 antibodies as RA. The PPV (96.1%) and
OR (80.9) we have observed are sufficiently high as to
propose this idea. The combination with the 2010 sero-
logical criteria was not necessary for this improvement,
as it did not significantly modify classification at the top
level.
In addition, the combined serological criteria permit-
ted a more precise stratification of the RA prediction.
For example, the high titres of RF or anti-CCP receive 3-
points in the 2010 ACR/EULAR criteria, whereas with
the combined criteria they were divided into three
groups: those with 3 antibodies would be classified dir-
ectly as RA (in the context of EA), the patients with 2
antibodies would remain in the 3-point level and the pa-
tients without concordant antibodies would receive a
lower score. This detailed prediction led to the improve-
ments reflected in the measures of model fit. Translating
the increase in precision into practical benefit would re-
quire integration of the serological scoring with other
clinical variables. According to the data obtained here,
the serological scores in the future classification criteria
will expand a larger range than currently. Predictably,
they will include a top-level equivalent to RA classifica-
tion provided that other criteria for EA are fulfilled and
three or four lower scores. As an initial exploration, we
set a four-level score for the serological component that
increased its weight. It resulted in better performance of
the classification than the obtained with the 2010 ACR/
EULAR criteria. The same happened when the relative
weights of each level were obtained from the logistic re-
gression. A more definitive scoring system will require
adjusting together the scores of the serological and non-
serological components for optimal performance. Add-
itional steps could be an assessment of the criteria by
experts, as done with the 2010 ACR/EULAR criteria,
and validation in independent EA patients including pa-
tients with any joint swelling, in place of the two swollen
joints required in our EA cohorts.
We restricted this study to explore the potential bene-
fit of concordance between RF, ACPA, and ACarPA
because of its novelty and the need to decide if ACarPA
could have any role in the classification of RA patients.
However, there is strong evidence indicating that ACPA
has more predictive value than RF (a feature also ob-
served in our EA patients) and it could be possible to
improve classification by differentiating between them.
Table 4 Overall fit of the models with different serological criteria for RA classification
Model fit 2010 ACR/EULAR a Concordance 2010 + Ccdc. 2010 + Ccdc.’
R2 0.452 0.454 0.483 0.483
AIC 1033.3 1033.8 1001.8 999.9
aThe serological criteria from the 2010 ACR/EULAR RA classification criteria, or based on the concordance of autoantibodies, and their combination without
modification (2010 + Ccd.) and after deleting the 1Ab stratum (2010 + Ccd’)
Table 5 Performance of the classification criteria for RA with different serological components
Serological
component
Scores a Logistic regression b
Specificity Sensitivity Accuracy Specificity Accuracy
2010 ACR/EULAR 72.6 78.8 75.8 73.7 77.1
Concordance 75.3 78.8 77.1 74.9 77.8
Ccdc. + 2010 76.4 80.6 78.8 76.8 78.6
aScores were as in the 2010 ACR/EULAR criteria; or depending on the number of concordant antibodies as 5 for 3, 3 for 2, and 1 for 1 antibodies; or combining
the two criteria as 5 for 3 or 2 antibodies with high titres, 3 for 3 or 2 antibodies with low titres, and 1 for 1 antibody irrespective of the titres
bClassification was done with logistic regression including the non-serological and the serological criteria and adjusted to obtain 80% sensitivity
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Also, the concordant presence of RF and anti-CCP could
be used to improve classification without the need for
new antibody determinations to the clinic. The PPV of
the two-antibodies concordance in our patients was
93.1% and the OR = 43.9, which are higher values than
those obtained with the 2010 serological criteria. These
approaches based on the concordance of RF and anti-
CCP or in differentiated scores for RF and anti-CCP will
improve classification to a lesser degree, but do not re-
quire new antibody determinations beyond the widely
available in the clinic. Finally, it is possible that other
autoantibodies, different from the three considered here,
could produce improvements in RA classification [5, 17].
Conclusions
Our results have shown the possibility of improving the
discrimination and precision of the serological compo-
nent in the RA classification of EA patients. Provided
that our results are replicated, and extended to patients
with one swollen joint, the top-level corresponding to
the presence of the 3 antibodies will be sufficient for RA
classification in the EA context. This step by itself could
increase the number of patients receiving appropriate
classification with a low fraction of false positives. How-
ever, the full advantage of the predictive power of anti-
body concordance will require modification of the
weights given to each stratum of RA patients in the
whole classification criteria.
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